StockCIK 1652130

Intellia Therapeutics, Inc. (NTLA): Insider Trades and Fund Holdings

In the past 12 months, Intellia Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 3 sales worth $310K; 2 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$310KSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.

Recent NTLA insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 6	Oct 2	Michael P. DubeCAO	CAO	▼ SELL	1,864	12.43	$23K	−2.8%	Form 4 ↗
Aug 24	Aug 20	John M. LeonardCEO	CEO	▼ SELL10b5-1	19,890	12.60	$251K	−1.7%	Form 4 ↗
Aug 24	Aug 21	John M. LeonardCEO	CEO	▼ SELL10b5-1	2,785	13.00	$36K	−0.2%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Michael P. Dube	CAO	0	$0	1	$23K	Oct 6, 2026
John M. Leonard	CEO	0	$0	2	$287K	Aug 24, 2026

Tracked funds that report NTLA

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	1,400,004	$23.7M	0.03%	▲ New

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →